SMM Global – Stock Market Manager Stock Market Manager simplifies distribution and disclosure of press releases, research and corporate news to financial terminals, print, broadcast and trade media, wire services, news agencies, databases, portals and websites.
Antibe Therapeutics, Inc. (ATBPF)
Antibe is a commercial-stage healthcare company focused on pain, inflammation and regenerative medicine. Antibe’s lead drug, ATB-346, targets the global need for a safer non-steroidal anti-inflammatory drug for chronic pain and inflammation. Antibe’s subsidiary, Citagenix Inc., is a leader in the promotion of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix operates in Canada through its direct sales force and internationally via a network of distributors. Antibe is focused on maximizing shareholder value by: (i) growing a portfolio of both pre-approval and commercial assets in the areas of pain, inflammation and regenerative medicine; and (ii) monetizing this portfolio through partnering and commercialization activity.
Description
Antibe is a commercial-stage healthcare company focused on pain, inflammation and regenerative medicine. Antibe’s lead drug, ATB-346, targets the global need for a safer non-steroidal anti-inflammatory drug for chronic pain and inflammation. Antibe’s subsidiary, Citagenix Inc., is a leader in the promotion of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix operates in Canada through its direct sales force and internationally via a network of distributors. Antibe is focused on maximizing shareholder value by: (i) growing a portfolio of both pre-approval and commercial assets in the areas of pain, inflammation and regenerative medicine; and (ii) monetizing this portfolio through partnering and commercialization activity.
Contact Information
15 Prince Arthur Avenue
Toronto, ONT M5R 1B2 Canada
Website: http://www.antibethera.com
Phone: (905) 570 5103
Email: info@antibethera.com
Financial Reporting/Disclosure
Reporting Status : International Reporting: TSX Venture Exchange
Audited Financials : Audited
Latest Report : Mar 31, 2016 Annual Report
CIK : 0001583682
Fiscal Year End 3/31
OTC Marketplace OTCQX International
Profile Data
SIC – Industry Classification : 2834 – Pharmaceutical preparations
Business Status : Development Stage Company a/o Sep 04, 2014
Incorporated In : Canada
Year of Inc. : 2013
Employees : 45 a/o Mar 27, 2015
Company Officers/Contacts
- Daniel Legault ┃ CEO
- John Wallace ┃ CSO
- Alian Wilson ┃ CFO
- Scott Curtis ┃ VP, Business Development
- David Vaughan ┃ Chief Development Officer
- Beth Chin ┃ Finance Manager
Company Directors
- Walt Macnee ┃ Chairman
- Roderick Flower
- Daniel Legault
- Samira Sakhia
- John Wallace
Service Providers
OTCQX Advisor
Merriman Capital, Inc.
250 Montgomery St.
16th Floor
San Francisco, CA, 94104
USA
Accounting/Auditing Firm
Zeifmans LLP Chartered Accountants
201 Bridgeland Avenue
Toronto, ONT, M6A 1Y7
Canada
Legal Counsel
Not Available
Investor Relations Firm
Not Available